BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 25684137)

  • 1. Design of an EGFR-targeting toxin for photochemical delivery: in vitro and in vivo selectivity and efficacy.
    Berstad MB; Cheung LH; Berg K; Peng Q; Fremstedal AS; Patzke S; Rosenblum MG; Weyergang A
    Oncogene; 2015 Oct; 34(44):5582-92. PubMed ID: 25684137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
    Ansell A; Jedlinski A; Johansson AC; Roberg K
    J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
    Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
    J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.
    Bull-Hansen B; Berstad MB; Berg K; Cao Y; Skarpen E; Fremstedal AS; Rosenblum MG; Peng Q; Weyergang A
    Oncotarget; 2015 May; 6(14):12436-51. PubMed ID: 26002552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.
    Selbo PK; Rosenblum MG; Cheung LH; Zhang W; Berg K
    PLoS One; 2009 Aug; 4(8):e6691. PubMed ID: 19690617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
    Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
    Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
    Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
    Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photochemical activation of the recombinant HER2-targeted fusion toxin MH3-B1/rGel; Impact of HER2 expression on treatment outcome.
    Bull-Hansen B; Cao Y; Berg K; Skarpen E; Rosenblum MG; Weyergang A
    J Control Release; 2014 May; 182():58-66. PubMed ID: 24637464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.
    Weyergang A; Cheung LH; Rosenblum MG; Mohamedali KA; Peng Q; Waltenberger J; Berg K
    J Control Release; 2014 Apr; 180():1-9. PubMed ID: 24531010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
    Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines.
    Oshima G; Wennerberg J; Yamatodani T; Kjellén E; Mineta H; Johnsson A; Ekblad L
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):491-9. PubMed ID: 22193422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
    Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
    J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Light-enhanced VEGF
    Weyergang A; Fremstedal AS; Skarpen E; Peng Q; Mohamedali KA; Eng MS; Cheung LH; Rosenblum MG; Waltenberger J; Berg K
    J Control Release; 2018 Oct; 288():161-172. PubMed ID: 30217739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
    Reilly EB; Phillips AC; Buchanan FG; Kingsbury G; Zhang Y; Meulbroek JA; Cole TB; DeVries PJ; Falls HD; Beam C; Gu J; Digiammarino EL; Palma JP; Donawho CK; Goodwin NC; Scott AM
    Mol Cancer Ther; 2015 May; 14(5):1141-51. PubMed ID: 25731184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery.
    Bhirde AA; Patel V; Gavard J; Zhang G; Sousa AA; Masedunskas A; Leapman RD; Weigert R; Gutkind JS; Rusling JF
    ACS Nano; 2009 Feb; 3(2):307-16. PubMed ID: 19236065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition.
    Fujiwara T; Eguchi T; Sogawa C; Ono K; Murakami J; Ibaragi S; Asaumi JI; Okamoto K; Calderwood SK; Kozaki KI
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1267-1272. PubMed ID: 30017201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma.
    Qi Z; Qiu Y; Wang Z; Zhang H; Lu L; Liu Y; Mathes D; Pomfret EA; Gao D; Lu SL; Wang Z
    Mol Oncol; 2021 Apr; 15(4):1054-1068. PubMed ID: 33540470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.